Market View 5th July 2023

View on market: Volatility Prevails, Market is searching for better value

Asian markets were to open lower on Wednesday in subdued trading following a holiday for U.S. markets. Major currencies were little changed. Futures for Hong Kong, Japan and Australia all declined, while contracts for the S&P 500 and Nasdaq 100 edged lower. Global stock market trading was light on Tuesday given the Independence Day celebration in the U.S. Europe’s Stoxx 600 inched up on trading volume that was a third lower than the 30-day average. Meanwhile, Brent crude was trading above $71 a barrel and West Texas Intermediate was above at $76-mark. The yield on the 10-year U.S. bond was trading at 3.84%, whereas Bitcoin was below 31,000-level. At 5:41 a.m., the GIFT Nifty, an early indicator of the Nifty 50 Index’s performance in India was up 0.06% or 12 points at 19,508.5.

Economic Calendar:

• USD : Initial Jobless Claims on 06th July, 2023
• USD : JOLTs Job Openings (May) on 06th July, 2023
• INR : Nikkei Services PMI (Jun) on 05th July, 2023
• INR : FX Reserves, USD on 07th July, 2023

Brokerage Radar:

MS ON RBL BANK: UW, TP Rs 180; Gross loan growth moderated to +4.1% QoQ vs. +5.1% QoQ in F4Q23; That said, retail loan growth was strong at 9% QoQ vs. +8% QoQ prior qtr; Retail deposit rose 3% QoQ vs. 4% QoQ in F4Q23. Liquidity improved (LCR at 129% vs. 126%)

NOMURA ON BANDHAN BK: Buy, TP Rs 325; CFO resigns, soft pre-1Q update

Reported loans growth of -5% q-q / +7% y-y.; Deposits growth muted at flat q-q/+17% y-y.; CASA deposits declined by -8% q-q/-3% y-y, with CASA ratio at 36% (-330bp q-q / -720bp y-y)

CLSA ON TATA COM: Buy, TP Rs 1755; Kaleyra acquisition will boost co’s CPaaS offering; Kaleyra is a CPaaS provider with proprietary platforms & revenue of $339m of which 54% is from US market; Deal attractively valued at 0.75x vs TCom’s own valuation 2.5x EV/Sales

International Markets

U.S & Europe:

Asian markets

ADR Watch:

Commodities & Currency

FIIs & DIIs:

News Update:

Bandhan Bank: Quarterly Business Updates Q1 FY24-Total deposits increased 16.6% YoY and 0.4% QoQ to Rs 1.08 lakh crore.-CASA deposits dropped 2.8% YoY and 8% QoQ to Rs 39,076 crore.-Retail deposits increased 5.9% YoY to Rs 77,329 crore.-Pan bank collection efficiency increased to 98% from 96% a year ago.

RBL Bank: Quarterly Business Updates Q1 FY24-Total deposits grew to Rs 85,638 crore, up 8% YoY and 1% QoQ.-CASA increased to Rs 31,927 crore, rising 12% YoY and 1% QoQ.-CASA ration improved to 37.3% from 36% a year ago.-Gross advances increased to Rs 74,792 crore, rising 20% YoY and 4% QoQ

IndusInd Bank: Quarterly Business Updates Q1 FY24-IndusInd Bank’s net advances increased 21% YoY to Rs 3.01 lakh crore-The Bank’s CASA ratio stood at 39.9% YoY-Deposits increased 15% YoY to Rs 3.47 lakh crore

LTIMindree: The company will replace HDFC Ltd. in Nifty 50 after mega HDFC merger. It will move from Nifty Next 50 to Nifty 50. The replacement will come into effect on July 13. The replacement will also be applicable to Nifty50 Equal Weight index.

Samvardhana Motherson International: The company, via unit SMRP B.V., will buy 81% stake in Yachiyo’s 4W business, housed under Japan’s Yachiyo Industry Co. Ltd. The stake is valued at JPY 22.9 billion (Rs 1,301 crore) for 100% stake. Honda Motor will own 19%, making it 81:19 joint venture. 

Jindal Steel & Power: The company will replace HDFC in Nifty 100. 

Mankind Pharma: The company will replace HDFC in Nifty 500, Nifty 200, Nifty Large Midcap 250 and Nifty Total Market.

Bandhan Bank: Bandhan Bank Chief Financial Officer Sunil Samdani has resigned, with effect from Sept. 30, and decided to explore professional opportunities outside the bank. The bank is in the process of identifying a suitable candidate for the office of CFO.

State Bank of India: The lender has approved to acquired entire stake held by unit SBI Capital Markets in SBICAP Ventures for a cash consideration of Rs 708.07 crore.

Aurobindo Pharma: Company’s breast cancer biosimilar product, BP02 Trastuzumab, developed by unit Curateq Biologics has met its primary endpoint in Phase III clinical trials and has shown equivalent efficacy to Herceptin biosimilar.

Source: Moneycontrol, Bloomberg Quint, Investing 

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.

For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)

Disclosure Appendix

Analyst Certification (For Reports)

Kiran Tahlani, Elite Wealth Limited, kirantahlani@elitestock.com

The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.

As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:

(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and

(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.

For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.

Research Excerpts

This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.

Company-Specific Disclosures

Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or e-mailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.

Options related research:

If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in

Other Disclosures

All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.

Ownership and material conflicts of interest Disclosure

Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.

Country Specific Disclosures

India – For private circulation only, not for sale.

Legal Entities Disclosures

Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth  Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in

EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:

1. Reports
2. a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;

(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;

(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;

2. Compensation

(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;

(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;

(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;

(d) EWL  or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;

(e) EWL or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.

3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL

Provided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or brokerage services transactions of the subject company.
(4) EWL or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL has never been engaged in market making activity for the subject company;
(6) EWL shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations.